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Objectives: To compare budesonide, a locally acting glucocorticoid with minimal systemic exposure, with
conventional glucocorticoid treatment and placebo in rheumatoid arthritis.
Methods: A double blind, randomised, controlled trial over 12 weeks in 143 patients with active
rheumatoid arthritis, comparing budesonide 3 mg daily, budesonide 9 mg daily, prednisolone 7.5 mg
daily, and placebo. Particular attention was paid to the pattern of clinical response and to changes in the
four week period following discontinuation of treatment.
Results: There were improvements in tender joint count and swollen joint count on budesonide 9 mg
compared with placebo (28% for tender and 34% for swollen joint counts, p,0.05). Prednisolone 7.5 mg
gave similar results, while budesonide 3 mg was less effective. ACR20 response criteria were met by 25%
of patients on placebo, 22% on budesonide 3 mg, 42% on budesonide 9 mg, and 56% on prednisolone
7.5 mg. A rapid and significant reduction in symptoms and signs in response to budesonide 9 mg and
prednisolone 7.5 mg was evident by two weeks and maximal at eight weeks. There was no evidence that
budesonide provided a different pattern of symptom control from prednisolone, or that symptoms became
worse than placebo treatment levels after discontinuation of glucocorticoid treatment. Adverse effects
attributable to glucocorticoids were equally common in all groups.
Conclusions: The symptomatic benefits of budesonide 9 mg and prednisolone 7.5 mg are achieved within
a short time of initiating treatment, are maintained for three months, and are not associated with any
rebound in symptoms after stopping treatment.
R
heumatoid arthritis is a disease of synovial inflamma-
tion in which the gut may have a pathophysiological
role.1–3 Attempts to influence joint inflammation by
altering the antigen load to the gut have used antibiotics,
diet, and fasting.4–6 Gut infection or inflammation is
associated with arthritis in Whipple’s disease and the
spondylarthropathies (ankylosing spondylitis, reactive arthri-
tis, and arthritis of inflammatory bowel disease).7 8 The
ileocaecal region is an area of particular interest in the search
for a pathophysiological link between the gut mucosal
immune system and joint inflammation.
Glucocorticoids are effective in suppressing the symptoms
of inflammation in rheumatoid arthritis in the short9 and
medium term,10 11 but long term continuing benefit has been
questioned.12
Budesonide (EntocortH) is a glucocorticoid that is for-
mulated in controlled ileal release (CIR) capsules, which are
designed to release budesonide mainly in the ileocaecal
region. Budesonide is a potent non-halogenated synthetic
glucocorticosteroid which undergoes an extensive degree of
biotransformation (approximately 90%) in the liver to
metabolites with low glucocorticosteroid activity. The gluco-
corticosteroid activity of the major metabolites 6b-hydro-
xybudesonide and 16a-hydroxyprednisolone is less than 1%
of that of budesonide. Thus budesonide has rapid and
extensive first pass metabolism in the liver. As a result it
has proved an effective method of delivering high activity of
glucocorticoid to the gut with relatively low plasma con-
centrations,13 14 thus offering a reduced risk of systemic side
effects and enhanced tolerability compared with conven-
tional glucocorticoid treatment. The efficacy of budesonide in
the treatment of ulcerative colitis and Crohn’s disease has
been demonstrated in clinical studies using enema and CIR
capsules, respectively.15–18
This study is based on the hypothesis that budesonide CIR
might normalise and modify the intestinal immune response
and thereby indirectly induce and maintain control of the
joint inflammation over and above the effect of glucocorticoid
systemically available. If so, the response to budesonide
might differ from the response to other oral glucocorticoids
such as prednisolone given in a dose that produces equivalent
systemic glucocorticoid concentrations. We therefore under-
took a randomised, double blind, placebo controlled trial of
the symptom relieving efficacy over 12 weeks of budesonide
CIR 9 mg daily in active rheumatoid arthritis compared with
placebo. Additional treatment arms included budesonide CIR
3 mg daily and prednisolone 7.5 mg daily, as the clinical
response to prednisolone is not well characterised over this
time period. In addition to overall efficacy at 12 weeks,
particular attention was paid to the shape of the symptom
response curves to assess any difference in pattern between
budesonide and prednisolone. The study subjects were
followed in double blind fashion for four weeks after
discontinuation of trial medication to monitor the pattern
of symptom return following each treatment arm.
METHODS
Objectives
The primary objective was to compare the symptom relieving
capacity of budesonide CIR 9 mg against placebo after 12
weeks treatment in patients with rheumatoid arthritis. The
primary outcome variables were tender joint count and
swollen joint count. The secondary objectives were to
compare the symptom relieving efficacy of budesonide CIR
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9 mg, budesonide CIR 3 mg, prednisolone 7.5 mg, and
placebo after 12 weeks of treatment; to investigate whether
there is any indication of a difference in symptom relief
between the study treatments at the beginning of the
treatment period and after the study treatment was with-
drawn; to assess quality of life during the study; and to assess
safety of the treatments during the study, concentrating
particularly on potential systemic side effects of glucocorti-
coids.
The study was approved by the local research ethics review
body at each participating institution.
Design
The study was a randomised, double blind, double dummy,
placebo controlled, multicentre study with four parallel
treatment groups: budesonide CIR 9 mg; budesonide CIR 3
mg; prednisolone 7.5 mg; or placebo once daily. Treatment
was for 12 weeks, with a further four weeks of follow up. The
double blind nature of the study was maintained until after
all patients had completed the follow up period. There were
16 recruitment centres in all, in Belgium, Sweden, and the
United Kingdom.
Patients
Outpatients with rheumatoid arthritis according to the
criteria of the American College of Rheumatology (ACR),19
with onset of the disease over the age of 16 years and who
met the inclusion criteria, were invited to take part in the
study. They were men or women aged between 18 and 80
years with active disease as shown by the presence of early
morning stiffness of at least 45 minutes and six or more
tender joints, of which at least three had soft tissue swelling
and tenderness. Patients were of functional capacity class I–
III according to Steinbrocker20 and had either no treatment
with or a stable dose of non-steroidal anti-inflammatory
drugs (NSAIDs) or analgesics for at least 30 days, no
treatment with or a stable dose of disease modifying anti-
rheumatic drugs (DMARDs) for at least 90 days, and no
glucocorticoids by any route for at least 30 days.
Patients were excluded from the study if they were
pregnant, planned pregnancy, or were breast feeding; if they
had systemic lupus erythematosus, polymyalgia rheumatica,
psoriatic arthropathy, spondyloarthropathy (ankylosing
spondylitis, reactive arthritis, undifferentiated spondyloar-
thropathy, and inflammatory bowel disease), amyloidosis,
active peptic ulcer disease, uncontrolled diabetes mellitus or
other significant disease as judged by the investigator; if
there was local or systemic infection that might contra-
indicate glucocorticoid use; if they had allergy to budesonide
or other glucocorticoids; if there was immunisation with live
viruses (for example, polio) or live bacteria (for example,
tubercle bacilli) during the previous 90 days; or if they had
undergone resection of the stomach or more than 100 cm of
the small bowel. Rheumatoid factor status and the presence
of radiographic erosions in the hands and feet were
determined at entry.
Outcome variables
Outcome variables were those recommended by OMERACT
(Outcome Measures in Rheumatology Clinical Trials).21
Primary outcomes were the number of tender joints and
the number of swollen joints (28 joint count).22 Secondary
outcomes were the patient’s assessment of pain (100 mm
visual analogue scale), the patient’s global assessment of
disease activity (100 mm visual analogue scale), the
clinician’s global assessment of disease activity (asympto-
matic, mild, moderate, severe, very severe), self report of
physical function (the health assessment questionnaire
(HAQ23) as adapted in the participating countries24 25), the
36 item short form health survey (SF-3626), and the acute
phase reactants C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR). Patient’s report of morning
stiffness (minutes) was also recorded. The ACR20 response
criteria27 were also applied (20% improvement in tender joint
count, 20% improvement in swollen joint count, and 20%
improvement in any three of pain, patient’s global assess-
ment, physician’s global assessment, disability, and the acute
phase response).
Safety variables
Safety variables included a specific inquiry for adverse events
and a checklist of potential glucocorticoid adverse effects
(moon face; buffalo hump; acne; hirsutism; purple skin
striae; bruising easily; hair loss; swelling of ankles; mood
swings; depression; insomnia), blood pressure, body weight,
and laboratory assessments including biochemistry, liver
enzymes, inflammatory markers, and blood glucose.
Measurement of adrenal function was undertaken the day
after discontinuation of treatment and will be reported
elsewhere.
Treatment
Following informed consent, patients were assessed over a
run-in period of up to two weeks to ensure they were eligible
for the study. Outcome and safety variables were measured,
and patients allocated to the next available study number.
Drugs were dispensed by the hospital pharmacy in relation to
the study number and in accordance with a predefined
sequence of randomly generated allocations kept in sealed
envelopes. Each patient was equally likely to be allocated to
any of the four treatment arms. In addition to their existing
drug treatment each patient took three study preparations
each day. One preparation was either budesonide 9 mg,
budesonide 3 mg, or budesonide placebo, all of which were






7.5 mg Placebo Total
Randomised 37 36 39 31 143
Lost to follow up 0 1 0 0 1
Included in intention to
treat analysis 37 35 39 31 142
Discontinued study
medication 7 6 3 7 23
Symptom deterioration* 5 3 1 3 12
Adverse event* 1 2 1 2 6
Other reasons* 3 0 1 2 6
Completed study
medication 30 30 36 24 120
Of 150 patients enrolled, five were not randomised because they were ineligible and two for other reasons.
*Five patients had two reasons for discontinuation.
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prepared as identical capsules. The other two preparations
were either prednisolone 5 mg plus prednisolone 2.5 mg, or
identical prednisolone 5 mg placebo and 2.5 mg placebo
tablets. Treatment was continued for 12 weeks. The study
drug treatment was then discontinued. Rescue treatment
(paracetamol 1 g up to four times daily) was available at the
patient’s discretion. The use of rescue treatment during the
previous weeks was recorded at each study visit. All non-
study drugs were continued unchanged throughout the study
period of 16 weeks. Adherence to the dosing instructions was
checked at two, four, eight, and 12 weeks by asking patients
if they had omitted any study medication and counting
returned unopened treatment packs. Patients who took less
than 80% of treatment, or who interrupted study treatment
for more than three consecutive days, were considered to be
non-adherent. Any drugs required for other conditions were
continued.
Doses of budesonide and prednisolone were chosen to
provide approximately equal systemic glucocorticoid effects
for the prednisolone treatment and for the higher dose of
budesonide. In a cortisol suppression dose–response study,28
29 mg budesonide produced similar responses to 20 mg
prednisolone.
Assessments
Following allocation to a study number at baseline, patients
were assessed and at weeks 0, 2, 4, 8, 12, and 16. Patient
discontinuing the study were, if possible, assessed at the time
of or soon after discontinuation. Unused study drugs and
rescue drugs were returned. The patient was assessed at 12
weeks after start of study treatment. Between weeks 13 and
16, patients completed weekly assessment cards including
records of pain, global assessment, and morning stiffness,
and recorded their drug intake in a notebook. This allowed an
evaluation of the rapidity of change in symptoms following
discontinuation of study treatment.
Study size
The study was powered to detect a difference in effect size for
swollen or tender joint counts between any two groups of 0.7
(equivalent to an absolute difference in change in joint count
of about 1). Based on published standard deviations, a=0.05
and b=0.80, a sample size of 35 patients per treatment group
was calculated, and the recruitment target set at 140 patients.
Statistical analysis
To compare the pattern of response for each variable by visual
inspection, means and 95% confidence intervals (CI) were
calculated for each time point for each treatment group,
expressed as a percentage of the combined baseline value for
that variable with all patients taken together, and used to
plot the figures. Absolute differences in mean values between
groups and their statistical significance were calculated from
analysis of variance, and are expressed in the tables after
adjustment for baseline differences. For patients who missed
one assessment the value of the previous assessment was
carried forward to that assessment (last value extended
principle). Early morning stiffness was not normally dis-
tributed and geometric means were used for statistical
calculations.
RESULTS
Of the 143 patients who were randomised into the study, one
patient did not receive any study preparations and is thus
not included in the analysis. The flow of patients through
the study is illustrated in table 1. Table 2 shows the







7.5 mg Placebo Combined
N 37 35 39 31 142
Age (years) 54.2 57.8 53.4 54.7 55.0
Proportion female (%) 70 77 62 77 71
Weight (kg) 73.5 74.6 73.9 71.4 73.4
Height (cm) 166 165 168 166 166
Disease duration (years) 13.1 8.5 7.0 7.2 9.0
Proportion with erosions (%) 84 66 54 87 72
Number taking NSAIDs 30 27 30 26 113
Number taking DMARDs 28 25 26 20 99
Disability (HAQ) score Baseline 1.61 1.57 1.51 1.52 1.55
12 weeks 1.57 1.41 1.11 1.48
Tender joint count Baseline 14.2 11.8 12.3 12.6 12.7
12 weeks 11.0 7.7 6.6 11.7
Swollen joint count Baseline 12.9 9.8 11.6 11.8 11.5
12 weeks 10.2 6.2 7.2 11.5
Patient’s assessment of pain (mm) Baseline 54.1 65.5 49.2 56.9 56.2
12 weeks 47.9 47.6 28.8 54.8
Patient’s global assessment of disease activity Baseline 50.6 59.0 54.4 54.4 54.5
12 weeks 48.1 42.4 31.8 55.8
Clinician’s global assessment of disease activity Baseline 3.1 3.2 3.0 3.1 3.1
12 weeks 2.8 2.7 2.3 3.0
Early morning stiffness (minutes) Baseline 111 98 93 105 102
12 weeks 54 73 73 94
C reactive protein (mg/l) Baseline 22.5 32.9 30.2 39.9 28.8
12 weeks 21.0 33.3 10.8 34.2
DMARD, disease modifying anti-rheumatic drug; HAQ, health assessment questionnaire; NSAID, non-steroidal anti-inflammatory drug.
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characteristics of the patients included in the intention to
treat analysis. The specific antirheumatoid drugs taken by the
patients were methotrexate (47%), sulphasalazine (31%),
hydroxychloroquine (6%), and others (16%) (minocycline,
gold, penicillamine). There were no significant differences
between groups for the baseline variables. The standard
deviations for the primary outcome variables for all groups
taken together were: tender joint count 5.72; swollen joint
count 5.06.
The mean and 95% confidence intervals (CI) for the
primary outcome measures (tender joint count and swollen
joint count) for each treatment group at each time point are
shown in fig 1 together with charts for pain, patient’s global
assessment, clinician’s global assessment, and disability
(HAQ). Differences in outcomes between treatment groups
at 12 weeks, adjusted for baseline differences, are shown in
table 3.
After adjustment for baseline differences, there were
significant improvements at 12 weeks in the budesonide 9
mg group, over and above the placebo response, in tender
joint count (3.65, 28.6%, p=0.014) and swollen joint count
(3.81, 32.9%, p=0.003). Of the secondary outcome variables,
there were improvements in patient’s assessment of disease
activity (15.9, 29.2%, p=0.012), physician’s assessment of
disease activity (0.45, 14.5%, p=0.019), and early morning
stiffness (geometric mean 0.37, 24.9%, p=0.016), and there
was a trend for pain improvement (21.7%, p=0.078).
Similar or slightly larger benefits over placebo were evident
for prednisolone 7.5 mg: tender joint count 4.83, 37.9%,
p=0.001; swollen joint count 3.67, 31.7%, p=0.003;
patient’s assessment 24.6, 45.1%, p=0.0002; physician’s
assessment 0.67, 21.5%, p=0.0004; early morning stiffness
0.473, 31.6%, p=0.002; and pain 22.3, 39.8%, p=0.001. In
addition, there was a clear improvement in functional
capacity in the prednisolone 7.5 mg group compared to both
placebo (0.38, 24.6%, p=0.0002) and budesonide 9 mg
(difference 0.27, 17.6%, p=0.004). The results for the
budesonide 3 mg generally fell between the placebo and
budesonide 9 mg groups, and were not significantly different
from either. The acute phase response, measured by C
reactive protein, showed a significant reduction greater than
that for placebo for budesonide 3 mg (geometric mean
difference 0.23, p=0.011) and prednisolone 7.5 mg (geo-
metric mean difference 0.48, p,0.00001), but not for
budesonide 9 mg. However, the budesonide 9 mg group
had similar significant reductions as the budesonide 3 mg
group at all other treatment time points.
At 12 weeks the proportion of patients (with 95% CI) who
met the ACR20 response criteria were: placebo, 25% (10% to
40%); budesonide 3 mg, 22% (9% to 35%); budesonide 9 mg,
42% (26% to 58%); and prednisolone 7.5 mg, 56% (40% to
72%). There was no significant difference between placebo
and budesonide 3 mg (p=0.56), or between budesonide 9
mg and prednisolone 7.5 mg (p=0.11), and both the latter
Figure 1 Changes in clinical symptoms during the study (means and 95% confidence intervals). Study treatment was for 12 weeks.
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were significantly different from both the former (p,0.001 to
p=0.02). These confirm the results from the individual
outcome measures, and suggest that over 12 weeks budeso-
nide 9 mg has an effect approaching that of prednisolone 7.5
mg for clinical symptoms.
The study included the SF-36,26 a measure of quality of
life, which contains mental (MCS) and physical (PCS)
subscales. The response on both subscales was non-signifi-
cant for budesonide 3 mg, showed a slight improvement of
10% more than placebo in the budesonide 9 mg group
(p=0.61 and p=0.060), and a clear improvement in the
prednisolone 7.5 mg group (PCS 27.8%, p,0.0001; MCS
16.4%, p=0.006).
After discontinuation of treatment, all groups returned
towards baseline values over the following four weeks.
Inspection of fig 1 does not suggest any difference in the
pattern of onset or the pattern of symptom recurrence
between the budesonide 9 mg group and the prednisolone
group. However, these data relate to an intention to treat
analysis, and a detailed analysis of those patients who
actually completed treatment to week 12 was therefore
undertaken to look specifically at the response to with-
drawal of treatment. There were 122 such patients (24,
30, 31, and 37 in placebo, budesonide 3 mg, budesonide
9 mg, and prednisolone 7.5 mg groups, respectively). In
all three treatment groups there were deteriorations in
the tender and swollen joint counts following treatment
withdrawal, which were significantly different from
zero, significantly different from the placebo group (which
had a non-significant improvement in both assess-
ments), and not statistically different from each other
(table 4).
Table 3 Differences between treatment groups in the change in primary and secondary outcome measures between baseline
and 12 weeks (after adjustment for baseline values)
Outcome
Difference from placebo
Budesonide 3 mg Budesonide 9 mg Prednisolone 7.5 mg
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Tender joint count 2.23 (20.63 to 5.1) 3.65* (0.75 to 6.54) 4.83*** (2.01 to 7.65)
Swollen joint count 1.53 (0.92 to 3.98) 3.81** (1.3 to 6.52) 3.67** (1.25 to 6.09)
Pain 6.6 (25.8 to 18.9) 11.4 (21.3 to 24) 22.3*** (10 to 34.6)
Disease activity (patient) 7.9 (24.7 to 20.5) 16.4* (3.6 to 29.3) 24.5*** (12.1 to 37)
Disease activity (physician) 0.25 (20.12 to 0.62) 0.45* (0.07 to 0.82) 0.66*** (0.3 to 1.03)
EMS 35 (29 to 80) 17 (228 to 62) 21 (223 to 64)
Geometric EMS (log10) 0.21 (20.08 to 0.5) 0.37* (0.07 to 0.67) 0.47** (0.18 to 0.77)
HAQ 0.009 (20.19 to 0.21) 0.107 (20.31 to 0.09) 0.383*** (0.188 to 0.578)
CRP (mg/dl) 6.6 (24.8 to 18.1) 1.9 (29.7 to 13.4) 21.8*** (10.5 to 33.1)
Geometric CRP (log10) 0.23* (0.05 to 0.41) 0.14 (20.04 to 0.32) 0.46*** (0.3 to 0.65)
PCS of SF-36 2 (22 to 6) 3.7 (20.4 to 7.8) 7.4*** (3.5 to 11.4)
MCS of SF-36 4.8 (20.8 to 10.4) 6.0* (0.4 to 11.7) 7.2** (1.7 to 12.8)
ESR (mm/h) 3 (24 to 10) 4 (23 to 11) 16*** (9 to 23)
ACR20 response (%) –3 (–17 to 23) 17* (5 to 29) 31** (16 to 46)
Outcome
Difference from budesonide 3 mg Difference from budesonide 9 mg
Budesonide 9 mg Prednisolone 7.5 mg Prednisolone 7.5 mg
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Tender joint count 1.42 (21.35 to 4.19) 2.59 (20.86 to 5.28) 1.18 (21.52 to 3.88)
Swollen joint count 2.28 (20.13 to 4.69) 2.14 (20.16 to 4.44) 0.14 (22.2 to 2.48)
Pain 4.8 (27.3 to 16.9) 15.7** (4.1 to 27.4) 10.9 (21.2 to 23.1)
Disease activity (patient) 8.5 (23.7 to 20.8) 16.6** (4.8 to 28.5) 8.1 (24 to 20.2)
Disease activity (physician) 0.2 (20.15 to 0.55) 0.42* (0.08 to 0.77) 0.22 (20.13 to 0.57)
EMS 19 (224 to 61) 15 (227 to 56) 4 (239 to 47)
Geometric EMS (log10) 0.16 (20.13 to 0.45) 0.26 (20.01 to 0.54) 0.1 (20.18 to 0.39)
HAQ 0.117 (20.31 to 0.07) 0.393*** (0.21 to 0.58) 0.276** (0.089 to 0.464)
CRP (mg/dl) 4.8 (26.3 to 15.8) 15.2** (4.4 to 25.9) 19.9*** (9.1 to 30.8)
Geometric CRP (log10) 0.09 (20.08 to 0.27) 0.24** (0.07 to 0.41) 0.33*** (0.16 to 0.5)
PCS of SF-36 1.7 (22.1 to 5.5) 5.4** (1.8 to 9.1) 3.7* (0 to 7.5)
MCS of SF-36 1.2 (24.1 to 6.5) 2.4 (27.5 to 2.6) 1.2 (26.5 to 4)
ESR (mm/h) 1 (26 to 8) 13*** (7 to 20) 12*** (6 to 19)
ACR20 response (%) 20** ( 6 to 34 ) 28** (12 to 44 ) 14 (24 to 32)
*p,0.05, **p,0.01, ***p,0.001.
ACR, American College of Rheumatology; CRP, C reactive protein; EMS, early morning stiffness; ESR, erythrocyte sedimentation rate; HAQ, health assessment
questionnaire; MCS, mental condition subscale of SF-36; PCS, physical condition subscale of SF-36; SF-36, 36 item short form health survey.
Table 4 Differences between treatment groups in the change in primary outcome measures during the four weeks after
discontinuation of study therapy (after adjustment for baseline values)










7.5 mg Prednisolone 7.5 mg
Tender joint count 3.967* 4.699* 6.423** 20.732 22.457 21.725
Swollen joint count 3.858** 4.012** 4.679** 20.154 20.821 20.667
Patients for whom 12 and 16 week data were available in each group: placebo, 24; budesonide 3 mg, 30; budesonide 9 mg, 31; prednisolone 7.5 mg, 37.
*p,0.05, **p,0.01.
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The occurrence of adverse effects is reported in tables 5 to
7. There were six serious adverse events in the study: five
hospital admissions for aggravation of rheumatoid arthritis
(two after completing the placebo treatment, two while
taking budesonide 3 mg, one after completing budesonide 3
mg and one after completing prednisolone); one 56 year old
woman taking budesonide 3 mg had angina of effort (she
also had aggravation of her rheumatoid arthritis); and one 58
year old man taking prednisolone with a history of ischaemic
heart disease died from coronary sclerosis. Adverse events
causing the patient to discontinue the study were few and
included gastrointestinal symptoms,2 heart symptoms,3 and
mood swings/insomnia.1 They occurred at similar rates in all
patient groups. The reported occurrence of the most common
adverse events (table 6) was evenly distributed in all
treatment groups and in the placebo group. Potential
glucocorticoid side effects (table 7), actively sought for by
checklist, were reported in many patients and occurred in all
patient groups, with no clinically important differences.
There were no statistically significant changes in mean
weight or blood pressure in any treatment group during the
study.
DISCUSSION
In this study of three doses of glucocorticoid compared with
placebo over 12 weeks we found a rapid and significant
reduction in the symptoms and signs of rheumatoid arthritis
in patients treated with budesonide 9 mg and prednisolone
7.5 mg, and a non-significant but consistent response to
budesonide 3 mg. The benefits were maximum at eight weeks
but were clearly evident by two weeks of treatment. This was
achieved with little in the way of additional adverse effects
over and above those noted in the placebo group.
The currently available Cochrane Collaboration meta-
analysis of moderate term low dose glucocorticoids for
rheumatoid arthritis10 29 draws attention to the paucity of
studies that directly assess the effectiveness of glucocorti-
coids for rheumatoid arthritis treatment, and many were of
poor methodological quality. Only seven12 30–35 of 34 studies
identified met minimum criteria for inclusion in the analysis,
and only four of these used a double blind design.12 31 33 34
These data present outcomes after periods of three months or
longer. A similar review of short term glucocorticoid
treatment9 concluded that there was clinical effectiveness
over one week. This review also noted that the initial
response (the mean difference between prednisolone and
placebo was 12 on the Ritchie index, which has a maximum
score of 7836) was much greater than the 2.4 tender joint
count reduction reported over three months.10 In the present
study, the reduction in tender joints was 4.83 in a scoring
system with a maximum score of 28 (and 3.67 for swollen
joints). This suggests that the reduction measured at one
week is similar to that sustained over three months in this
study. The standardised effect size in this study is 0.82 for
tender joints and 0.73 for swollen joints.
Analysis of the secondary outcome variables is less clear, as
the study was not powered primarily for that purpose.
Nevertheless, there is good evidence that budesonide 9 mg
and prednisolone 7.5 mg clearly reduce symptoms. In this
regard, prednisolone 7.5 mg generally produced a greater
improvement. However, it should be noted that the
serum levels of glucocorticoid will be higher at the time
of the patient assessment in the prednisolone group, as
the majority of assessments were undertaken in the
morning, the treatments were taken on waking, and the
absorption profile of budesonide means that peak
serum levels will not be attained for several hours after
ingestion. It may be that taking budesonide earlier,
possibly even on going to bed, might have resulted in a
greater effect.
It should also be recognised that patients in the study were
receiving other antirheumatoid treatment. The benefits of
budesonide 9 mg and prednisolone 7.5 mg in achieving an
ARC20 response in about half of the patients treated were in
addition to the disease control already achieved with other
treatments.








Evaluable patients 142 37 35 39 31
Exposure (days) 2872 2681 3255 2312
Number of adverse reactions (AE) 91 94 97 88 70
Number of patients with serious adverse
reactions 2 0 2 2
Number (%) of patients with AE 89 (63%) 33 (89%) 33 (94%) 33 (85%) 28 (90%)







Respiratory infection 7 4 6 1
Headache 4 5 6 1
Abdominal pain 4 3 4 2
Rheumatoid arthritis aggravated 6 3 0 3
Diarrhoea 2 2 2 3
Pain 1 2 3 1
Back pain 1 3 0 3
Haematuria 2 1 2 2
Infection, viral 4 1 0 0
Anaemia 1 2 0 2
Dyspepsia 2 0 2 1
Sweating increased 1 2 1 1
Total 35 28 26 20
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Our results suggest there was no additional effect of
budesonide over and above the systemic benefits of gluco-
corticoid treatment, in spite of a presumed strong local
effect on the terminal ileum. In other conditions associated
with bowel pathology the time course of the response may
be longer than the three months treatment period of the
present study. For example, in coeliac disease the skin
inflammation usually improves later than three months
after withdrawal of gluten. It is possible, therefore, that a
longer time course of treatment with budesonide would
be required to obtain additional benefits. If new evidence
were to point to such a possibility, then a longer term
study should be considered. Other conditions, such as
spondyloarthropathy, in which the gut has been implicated
more directly in the disease process, and where glucocorti-
coids are not normally the treatment of choice, may prove
more responsive to budesonide than to prednisolone. It
would be worthwhile carrying out a comparable study in
such patients.
While direct questioning about ‘‘steroid related’’ side effects
elicited many reports, these were of similar frequency in all
treatment groups, and many were also present at the screening
visit before any glucocorticoid treatment. This result questions
the notion of the selected category of potential GCS side effects
in this group of patents. It also indicates the need for care in
the interpretation of adverse effect reporting in non-blinded or
uncontrolled studies. No new adverse events were seen com-
pared with previous studies with budesonide in Crohn’s
disease. Neither were any adverse events reported after discon-
tinuation of the trial medication which might have suggested
adrenal insufficiency. Direct measurement of adrenal function
will be analysed and reported elsewhere. While there was an
increase in symptoms once glucocorticoids were discontinued,
patients became no worse off than if they had been taking
placebo treatment, and there was no evidence of a ‘‘rebound
effect’’ on discontinuation of glucocorticoid treatment.
Overall, this carefully conducted study shows that the
symptomatic benefits of budesonide 9 mg and prednisolone
7.5 mg are achieved within a week or two of initiating
treatment, are maintained for three months, and are not
associated with any ‘‘rebound’’ in symptoms after stopping
treatment.
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